Clearside Biomedical Inc at JPMorgan Healthcare Conference Transcript
All right. Welcome back to the 38th JPMorgan Annual Healthcare Conference. My name is Matt Bannon. I'm one of the junior analysts here at JPMorgan. I'm happy to introduce our next presenting company, Clearside Biomedical, and presenting on behalf of the company is Chief Medical Officer, Tom Ciulla. Tom?
Well, thank you. Once again, I'm Tom Ciulla, Chief Medical Officer. And as a retina specialist, I'm thrilled to be part of a potential paradigm shift in the way we treat retinal diseases.
I may make some forward-looking statements during this presentation, which are summarized in this slide and all our filings are online.
We have a versatile therapeutic platform with the SCS Microinjector with proprietary drug formulations that target the suprachoroidal space. We're basically focused on small molecules and gene therapies to develop an internal research and development pipeline and external
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |